The impressive effects of LY3475766 in this study were consistent with an upregulation of LPL activity in oxidative tissues, and suggest that LY3475766 should be effective in patients with hypertriglyceridemia, provided that at least some LPL is bioavailable6. The gene discussed is LPL; the disease is hypertriglyceridemia.